TNFRSF9 and cancer: The mechanisms that can suppress antitumor immune responses in the context of cancer are various and this gives the rationale to the use of CD137 targeting in combination with other strategies aimed at removing these regulatory constraints [44,109,111,112,113,117,136,137].